comparemela.com

Latest Breaking News On - Dr lal pathlabs stock - Page 1 : comparemela.com

Kotak Institutional Equities says worst of price war in diagnostics behind us but stays cautious; here s why

The brokerage has a sell call on Dr Lal with a target price of ₹1,740, implying a potential downside of over 30 percent. Meanwhile, it has a reduce call on Metropolis with a target price of ₹1,350, indicating an over 7 percent downside.

vimarsana © 2020. All Rights Reserved.